UK Markets open in 2 hrs 57 mins

Apontis Pharma AG (APPH.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
7.98-0.32 (-3.86%)
At close: 09:50PM CET
Full screen
Loading interactive chart…
  • EQS Group

    APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill

    EQS-News: APONTIS PHARMA AG / Key word(s): Product LaunchAPONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill 31.01.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill New Single Pill with potential peak sales of approx. EUR 1.3 million Market launch already planned for mid

  • EQS Group

    APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals

    EQS-News: APONTIS PHARMA AG / Key word(s): Product LaunchAPONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals 29.11.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals Continuous expansion of the Single Pill portfolio to meet the target of at least 20 Single Pil

  • EQS Group

    APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets

    EQS-News: APONTIS PHARMA AG / Key word(s): 9 Month figures/Quarterly / Interim StatementAPONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets 10.11.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets Superiority of Single Pill therapy confirmed in